PTGX Protagonist Therapeutics, Inc
Q3 2025 10-Q
Protagonist Therapeutics, Inc (PTGX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New FDA disruption risk triggered by mass federal employee layoffs since January 2025 and ongoing government shutdown starting October 2025
- • Updated macroeconomic risk from U.S. tariffs up to 100% on imported branded pharmaceuticals announced September 2025 with unclear implementation timing
Quarterly Financial SummaryXBRL
Revenue
$5M
Net Income
-$39M
Operating Margin
-985.2%
Net Margin
-834.9%
ROE
-6.1%
Total Assets
$702M
Source: XBRL data from Protagonist Therapeutics, Inc Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Protagonist Therapeutics, Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.